Patents Assigned to TAHO PHARMACEUTICALS, LTD.
-
Publication number: 20240316026Abstract: The present disclosure provides an apixaban film product for treatment and prevention of thrombosis and related disorders. Also provided is a method of making the film product. The film product comprises an anticoagulant and a hydrophilic cellulosic polymer.Type: ApplicationFiled: May 31, 2024Publication date: September 26, 2024Applicant: TAHO Pharmaceuticals Ltd.Inventors: Tachien LU, Catherine LEE
-
Patent number: 12036216Abstract: The present disclosure provides an apixaban film product for treatment and prevention of thrombosis and related disorders. Also provided is a method of making the film product. The film product comprises an anticoagulant and a hydrophilic cellulosic polymer.Type: GrantFiled: June 3, 2022Date of Patent: July 16, 2024Assignee: TAHO Pharmaceuticals Ltd.Inventors: Tachien Lu, Catherine Lee
-
Patent number: 11304933Abstract: A fast acting orally disintegrating film (ODF) for treatment of various medical conditions including emesis that has a simple formulation, easy to manufacture and has similar pharmacokinetic profile to currently commercially available orally administered drug products is provided. The ODF comprises an active pharmaceutical ingredient such as ondansetron or a pharmaceutical acceptable salt thereof in an amount of 2 to 24 mg, at least one hydrophilic film forming polymer in an amount of at least 8% by weight of the film, wherein the at least one hydrophilic film forming polymer is characterized by having a molecular weight of 5000 to 50000 Da, and a water soluble excipient in an amount of 10 to 30% by weight of the film.Type: GrantFiled: September 13, 2019Date of Patent: April 19, 2022Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Catherine Lee, Chien-Chiao Wang
-
Patent number: 11229611Abstract: The present invention relates to transdermal drug delivery system of pharmaceutical compositions, which have a satisfactory in-vitro performance and good bioavailability. In particular, the transdermal pharmaceutical composition of clobazam in the present invention includes a micro-emulsion in liquid or semi solid form, in a dosage form adapted for transdermal delivery (e.g., transdermal patch) for treatment of certain types of epilepsy and anxiety for continues application.Type: GrantFiled: April 23, 2021Date of Patent: January 25, 2022Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Moonika Sari Widjajana, Tachien Lu, Catherine Lee
-
Patent number: 10758546Abstract: The present invention provides a transdermal delivery system, which comprises a drug-containing matrix layer comprising: galantamine or its pharmaceutically acceptable salt as an active ingredient; and a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive.Type: GrantFiled: July 20, 2016Date of Patent: September 1, 2020Assignees: Industry-Academic Cooperation Foundation, TAHO Pharmaceuticals Ltd.Inventors: Hoo-kyun Choi, Myung-kwan Chun
-
Patent number: 10537532Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.Type: GrantFiled: April 24, 2018Date of Patent: January 21, 2020Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Shen-Yung Kao, Taijung Wu, Catherine Lee
-
Patent number: 10456378Abstract: A fast acting orally disintegrating film (ODF) for treatment of various medical conditions including emesis that has a simple formulation, easy to manufacture and has similar pharmacokinetic profile to currently commercially available orally administered drug products is provided. The ODF comprises an active pharmaceutical ingredient such as ondansetron or a pharmaceutical acceptable salt thereof in an amount of 2 to 24 mg, at least one hydrophilic film forming polymer in an amount of at least 8% by weight of the film, wherein the at least one hydrophilic film forming polymer is characterized by having a molecular weight of 5000 to 50000 Da, and a water soluble excipient in an amount of 10 to 30% by weight of the film.Type: GrantFiled: November 14, 2016Date of Patent: October 29, 2019Assignee: TAHO Pharmaceuticals Ltd.Inventors: Catherine Lee, Chien-Chiao Wang
-
Patent number: 10420733Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.Type: GrantFiled: April 24, 2018Date of Patent: September 24, 2019Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Shen-Yung Kao, Taijung Wu, Catherine Lee
-
Publication number: 20180296495Abstract: A fast acting orally disintegrating film (ODF) for administration of local anesthetic for alleviating physical and psychological discomfort in the oral cavity during procedures such as dental procedures or for relieving pain generally such as toothaches. The ODF comprises an active pharmaceutical ingredient such as lidocaine free base or a pharmaceutically acceptable salt thereof in a therapeutically acceptable amount such as about 24 mg, at least one primary hydrophilic film forming polymer, at least one secondary hydrophilic film forming polymer, wherein the ratio of the primary hydrophilic film forming polymer to the secondary hydrophilic film forming polymer is about 1:1 to about 20:1 by weight. The ODF further comprises a plasticizer wherein the ratio of the total weight of primary and secondary hydrophilic film forming polymer to the weight of the plasticizer is about 4:1 to about 4:3.Type: ApplicationFiled: June 30, 2016Publication date: October 18, 2018Applicant: TAHO PHARMACEUTICALS LTD.Inventors: Catherine Lee, Chien-Chiao Wang, Fang-Chu Lin
-
Patent number: 9993445Abstract: Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent. The combined flavors successfully masked atomoxetine hydrochloride's bitter smell and/or taste which makes it a novel palatable pharmaceutical composition. The viscosity agent improves the oral pharmaceutical composition's consistency and provides a smooth texture which makes it easy to swallow. More specifically, the oral pharmaceutical composition comprises effective amounts of: (a) atomoxetine or the pharmaceutically acceptable salts thereof; and (b) a taste-masked liquid carrier. Also provided is a method for making the aqueous solution of atomoxetine. The present disclosure also provides methods of using oral pharmaceutical composition for the treatment of a subject having a disorder treatable by the administration of atomoxetine.Type: GrantFiled: November 29, 2017Date of Patent: June 12, 2018Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Chin Chung Lin, Chien-Chiao Wang, Catherine Lee
-
Patent number: 9980921Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.Type: GrantFiled: June 27, 2017Date of Patent: May 29, 2018Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Shen-Yung Kao, Taijung Wu, Catherine Lee
-
Patent number: 9855228Abstract: Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent. The combined flavors successfully masked atomoxetine hydrochloride's bitter smell and/or taste which makes it a novel palatable pharmaceutical composition. The viscosity agent improves the oral pharmaceutical composition's consistency and provides a smooth texture which makes it easy to swallow. More specifically, the oral pharmaceutical composition comprises effective amounts of: (a) atomoxetine or the pharmaceutically acceptable salts thereof; and (b) a taste-masked liquid carrier. Also provided is a method for making the aqueous solution of atomoxetine. The present disclosure also provides methods of using oral pharmaceutical composition for the treatment of a subject having a disorder treatable by the administration of atomoxetine.Type: GrantFiled: December 14, 2016Date of Patent: January 2, 2018Assignee: TAHO PHARMACEUTICALS LTD.Inventors: Chin Chung Lin, Chien-Chiao Wang, Catherine Lee
-
Publication number: 20170056374Abstract: A fast acting orally disintegrating film (ODF) for treatment of various medical conditions including emesis that has a simple formulation, easy to manufacture and has similar pharmacokinetic profile to currently commercially available orally administered drug products is provided. The ODF comprises an active pharmaceutical ingredient such as ondansetron or a pharmaceutical acceptable salt thereof in an amount of 2 to 24 mg, at least one hydrophilic film forming polymer in an amount of at least 8% by weight of the film, wherein the at least one hydrophilic film forming polymer is characterized by having a molecular weight of 5000 to 50000 Da, and a water soluble excipient in an amount of 10 to 30% by weight of the film.Type: ApplicationFiled: November 14, 2016Publication date: March 2, 2017Applicant: TAHO Pharmaceuticals Ltd.Inventors: Catherine Lee, Chien-Chiao Wang
-
Patent number: 9066886Abstract: Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol; and an acrylate polymer.Type: GrantFiled: August 22, 2008Date of Patent: June 30, 2015Assignee: TAHO PHARMACEUTICALS, LTD.Inventor: Hoo-Kyun Choi